2025-03-04 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**0. Summary of Key Figures:**

* **Cumulative Return (MRK):** 51.81%
* **Cumulative Return (VOO):** 116.17%
* **Return Difference (MRK vs VOO):** -64.4% (MRK underperformed VOO significantly)
* **Current Price:** $92.25
* **RSI:** 63.89
* **PPO:** 1.0385
* **Expected Return (vs S&P 500):** 39.3% (Long-term, 2+ years)


**1. Performance Comparison:**

Merck & Co Inc (MRK) is a leading pharmaceutical company known for its innovative medicines and vaccines.  MRK's cumulative return of 51.81% significantly lags behind the S&P 500's (VOO) return of 116.17% over the analyzed period.  The -64.4% difference places MRK at the 15.7th percentile of its historical performance relative to the S&P 500, indicating underperformance.

**Alpha and Beta Analysis:**

The provided data shows inconsistent alpha and beta values across different periods. While some periods show positive alpha (outperformance relative to the market), others show negative alpha. Beta values are consistently high, indicating high volatility and sensitivity to market movements.  The high beta suggests that MRK's performance is strongly correlated with overall market trends.  Further investigation is needed to understand the drivers behind the fluctuating alpha and the persistently high beta.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | -2.0% | 11.8% | -0.1 | 110.1 |
| 2016-2018  | 46.0% | 11.8% | 0.5 | 154.0 |
| 2017-2019  | 44.0% | 11.8% | 0.3 | 188.3 |
| 2018-2020  | 32.0% | 9.4% | 0.2 | 174.8 |
| 2019-2021  | 3.0% | 14.3% | 0.2 | 177.8 |
| 2020-2022  | 47.0% | 14.3% | 0.2 | 265.7 |
| 2021-2023  | 55.0% | 14.3% | 0.3 | 268.4 |
| 2022-2024  | 21.0% | 9.5% | 0.3 | 251.6 |
| 2023-2025  | -35.0% | 9.5% | 0.1 | 233.3 |


**2. Recent Price Movement:**

* **Closing Price:** $92.25
* **Last Market Price:** $92.445 (Slight increase from previous close)
* **5-Day Moving Average:** $90.98
* **20-Day Moving Average:** $89.07
* **60-Day Moving Average:** $95.97

The current price is above the 5-day and 20-day moving averages, suggesting short-term upward momentum. However, it's below the 60-day moving average, indicating a potential short-term correction or consolidation phase.  The slight price increase from the previous close (0.21%) is not significant enough to be considered a sharp jump.


**3. Technical Indicators:**

* **RSI (63.89):** Suggests the stock is neither overbought nor oversold, indicating a relatively neutral momentum.
* **PPO (1.04):**  A positive PPO value suggests a bullish trend.
* **Relative Strength Change (20-day):** +4.9% indicates recent upward momentum.

The combination of these indicators points towards a moderately bullish outlook in the short term.


**4. Recent Earnings Analysis:**

The provided earnings data is inconsistent, with duplicate entries for 2024-11-06.  The data lacks clear trends, requiring more complete and consistent data for meaningful analysis.  Revenue appears relatively stable, but EPS fluctuates considerably.  Further data cleaning and analysis are needed.


| 날짜       | EPS  | 매출        |
|------------|------|-------------|
| 2024-11-06 | 1.25 | 16.66 B$    |
| 2024-08-05 | 2.15 | 16.11 B$    |
| 2024-05-03 | 1.88 | 15.78 B$    |
| 2023-11-03 | 1.87 | 15.96 B$    |
| 2024-11-06 | 1.87 | 15.96 B$    |


**5. Financial Information:**

Revenue shows a generally upward trend, although there are some minor fluctuations. Profit margins are consistently high, indicating strong profitability. Equity is also increasing, suggesting healthy financial growth. ROE is variable, with some quarters showing very high returns and one showing a negative return.  More historical data would aid in understanding the fluctuations in ROE.


Revenue and Profitability:

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $15.62B | 75.50% |
| 2024-09-30 | $16.66B | 75.51% |
| 2024-06-30 | $16.11B | 76.76% |
| 2024-03-31 | $15.78B | 77.56% |
| 2023-12-31 | $14.63B | 73.26% |

Capital and Profitability:

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-12-31 | $46.31B | 8.08% |
| 2024-09-30 | $44.50B | 7.09% |
| 2024-06-30 | $43.58B | 12.52% |
| 2024-03-31 | $40.36B | 11.80% |
| 2023-12-31 | $37.58B | -3.26% |


**6. Overall Analysis:**

MRK has shown significant underperformance compared to the S&P 500 over the analyzed period. While the company demonstrates strong profitability and revenue generation, its high beta and fluctuating alpha suggest considerable market sensitivity and unpredictable returns. Short-term indicators suggest a neutral to slightly bullish outlook.  However, the long-term expected return of 39.3% relative to the S&P 500 suggests potential for outperformance with a long-term investment strategy (2+ years).  More complete and consistent financial data, along with a deeper dive into the company's strategic initiatives and market position, is needed for a more comprehensive assessment.  The inconsistent earnings data requires clarification.
